1	UNITED STATES DISTRICT COURT
2	WESTERN DISTRICT OF NEW YORK
3	
4	
5	
6	
7	X
8	BAUSCH & LOMB, INC., et al., 13-CV-6498(JWF) Plaintiffs
	Rochester, New York
10	VITAMIN HEALTH, INC. July 29, 2016 Defendant 8:30 a.m.
11	X
12	
13	
14	TRANSCRIPT OF PROCEEDINGS
15	BEFORE THE HONORABLE JONATHAN W. FELDMAN UNITED STATES MAGISTRATE JUDGE
16	UNITED STATES MAGISTRATE UUDGE
17	
18	
19	
20	
21	
22	
23	COURT REPORTER: Christi A. Macri, FAPR-CRR
24	Kenneth B. Keating Federal Building 100 State Street, Room 2120
25	Rochester, New York 14614

1	APPEARANCES
2	
3	HARTER, SECREST AND EMERY, LLP BY: ERIKA N.D. STANAT, ESQ.
4	· ·
5	- and - FITZPATRICK, CELLA, HARPER & SCINTO
6	BY: DAMIEN N. DOMBROWSKI, ESQ. STEVEN C. KLINE, ESQ.
7	1290 Avenue of the Americas New York, New York 10104-3800
8	Appearing on behalf of the Plaintiffs
9	
10	CARLSON GASKEY & OLDS, P.C. BY: STEVEN C. SUSSER, ESQ. BRIAN S. TOBIN, ESQ.
11	MICHAEL A. SZYPA, ESQ. 400 West Maple Road, Suite 350
12	Birmingham, Michigan 48009 Appearing on behalf of the Defendant
13	Appearing on Denair of the Defendant
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

PROCEEDINGS

2

1

6

7

8

9

11

12

13

14

16

17

18

19

21

2.2

23

24

08:36:35AM10

08:37:02AM15

08:37:28AM20

08:37:44AM25

THE CLERK: Judge Feldman presiding. Please be
4 seated. This is Bausch & Lomb vs. Vitamin Health, 13-CV-6498.

08:16:59AM 5 July 29, 2016.

MAGISTRATE JUDGE FELDMAN: Good morning. We've got a lot to do here and not a lot of time to do it in so I want to just go over what I want to accomplish.

I want to talk about rulings on depositions; I want to have some oral argument on the motion to dismiss; we need to address the designations of excerpts of deposition testimonies on the Doctrine of Equivalents -- Mr. Meyering, Mr. Balaram and Mr. Ferris; I want to talk about the validity summary judgment motion filed by Bausch & Lomb; and Vitamin Health's summary judgment motion on the issue of prosecution estoppel; I want to talk about what questions will be presented to the jury on enablement; I want to talk a little bit about the schedule next week; and any changes to the witness list.

So unless somebody has a particular item they want to address first, I thought I would just go in order here.

MR. SUSSER: That's fine, Your Honor.

magistrate judge feldman: Okay. Starting with the ruling on the depositions, I'm almost through them and I will give you my rulings, at least preliminarily, Monday morning

before we start with jury selection. 2 I assume most of these depositions are video depositions? 3 4 MR. DOMBROWSKI: I think roughly half and half. don't think there's --08:38:01AM 5 MAGISTRATE JUDGE FELDMAN: Well, I know you would 6 7 have to make on the video depositions edits depending on my rulings. So I don't know how much time you need to do that, 8 but you might want to consider the order that you play the depositions, the video depositions, if you need time to do 08:38:13AM10 11 that. MR. KLINE: Well, I think if we have the ruling by 12 13 Monday, I know none are going on on Monday so --14 MAGISTRATE JUDGE FELDMAN: Okay, fine. Then let's 08:38:28AM15 get to some argument on the motion to dismiss, which I know 16 the timing of this is kind of problematic, but I think we've 17 got to get it resolved. 18 So who should I ask questions to from Bausch & Lomb 19 here? 08:38:44AM20 MR. DOMBROWSKI: I can answer questions on that. MAGISTRATE JUDGE FELDMAN: Okay. You sued Vitamin 21 Health for products which you allege have infringed or are 22 23 currently infringing on both your '297 and your '522 patents, 24 right?

MR. DOMBROWSKI: Correct.

08:39:02AM25

MAGISTRATE JUDGE FELDMAN: Okay. Are you aware of 1 2 any current Vitamin Health product that infringes on the '522 patent that you're not including in your complaint? 3 MR. KLINE: We're not aware of any. 4 MAGISTRATE JUDGE FELDMAN: Okay. I mean, clearly if 08:39:14AM 5 they were marketing something and making money off of it, you 6 7 would be concerned about it if it violated your patent? MR. DOMBROWSKI: I think that's right. 8 MAGISTRATE JUDGE FELDMAN: Okay. Now, we're 9 scheduled to commence the trial on Monday. I think your 08:39:28AM10 11 motion was filed on Wednesday, but yesterday I sent you this Hillman case because I was interested in the case or 12 13 controversy discussion in there. I was well aware that it was a case involving a 14 08:39:44AM15 defendant who had filed a declaratory judgment action on

I was well aware that it was a case involving a defendant who had filed a declaratory judgment action on patent validity, but it was the case or controversy discussion related to that invalidity claim that was of interest to me.

Now, in that case the plaintiff offered to dismiss the infringement claim with prejudice, which included a covenant not to sue for any infringing acts for past or current products.

And the defendant there argued that the declaratory judgment action on validity would survive that because they wanted a promise not to sue for any future products.

Is that your reading of the case?

08:40:24AM25

08:40:04AM20

16

17

18

19

21

2.2

23

24

MR. DOMBROWSKI: It is. 1 2 MAGISTRATE JUDGE FELDMAN: Okay. Now here you're moving to dismiss the '522 patent with prejudice. Is it 3 inherent on a dismissal with prejudice under the facts here 4 08:40:40AM 5 that you're not going to be suing on any past or current products? 6 MR. DOMBROWSKI: I think that's correct. 7 the claim preclusion rules, you know, in a later action it 8 would be limited to the products that were essentially the same as the products in the --08:40:52AM10 11 MAGISTRATE JUDGE FELDMAN: Okay. And all the 12 products that you are aware of that are infringing on the '522 13 patent are within the purview of this motion to dismiss with 14 prejudice? 08:41:03AM15 MR. DOMBROWSKI: Current, the current accused 16 products, correct. 17 MAGISTRATE JUDGE FELDMAN: You're not aware of any 18 products that infringe or allegedly infringe that you haven't 19 sued on? 08:41:11AM20 MR. DOMBROWSKI: That's my understanding, yeah. 21 MAGISTRATE JUDGE FELDMAN: Okay. And it's the same analysis with respect to the false advertising claims, the 22 23 action would be dismissed with prejudice as to the products 24 covered by the complaint, correct? 08:41:24AM25 MR. DOMBROWSKI: Correct.

MAGISTRATE JUDGE FELDMAN: Okay. Who do I ask 1 2 questions to here? MR. TOBIN: Me, Your Honor. 3 MAGISTRATE JUDGE FELDMAN: Like the defendant 4 seeking the declaratory judgment in Hillman, you agree that 08:41:40AM 5 dismissal with prejudice is essentially a covenant not to sue 6 you for any past or current products that may infringe on 7 your -- on the '522 patent? 8 9 MR. TOBIN: Your Honor, I believe that with Hillman, there was both the dismissal with prejudice as well as the 08:41:58AM10 11 covenant not to sue. 12 MAGISTRATE JUDGE FELDMAN: I understand that, but as 13 a practical matter, wouldn't a dismissal with prejudice give 14 you the same benefit as a covenant not to sue when you have a 08:42:13AM15 representation here that unless there's some product you're 16 hiding from them that you haven't marketed, that it covers all 17 the products? 18 MR. TOBIN: Well --19 MAGISTRATE JUDGE FELDMAN: Past or current products? MR. TOBIN: -- I think there's a question as to what 08:42:28AM20 21 past or current or future products they're referring to. MAGISTRATE JUDGE FELDMAN: What is the question? 2.2 23 What product do you have that is not within the scope of this 24 lawsuit? 08:42:46AM25 MR. TOBIN: I believe there's at least one product

that -- and I don't know if it's within the scope of this 2 lawsuit. You know, the four corners of the complaint were pretty broad, the contentions were different. 3 4 But if you look at the four corners of the complaint, I think they're accusing all of our AREDS and AREDS 08:42:58AM 5 2 products of infringing, but there are certain products of 6 ours which they haven't pursued further. 7 MAGISTRATE JUDGE FELDMAN: Okay. In your memo you 8 9 stated you -- even with the dismissal with prejudice, you're open to suit on current products that are not included in the 08:43:14AM10 11 '522 complaint. What is that product you're referring to? 12 13 MR. TOBIN: Any product that wouldn't be in the 14 complaint. I mean --08:43:25AM15 MAGISTRATE JUDGE FELDMAN: You know your products. 16 What product are you worried about? 17 MR. TOBIN: Well, I think the question is we're 18 worried about the current as well as the future products here, 19 Your Honor. 08:43:33AM20 MAGISTRATE JUDGE FELDMAN: Take future out of it, 21 we'll get to future. 2.2 But current or past product -- past product doesn't 23 really matter, but current product, what current product are you worried about? 24

MR. TOBIN: I think as it relates to the current

08:43:43AM25

- products, Your Honor, the one product that I can think of
 offhand here today they have not pursued anything on would be
 the Viteyes Complete product as an example.

 MR. KLINE: I'm not certain what the formulation of
 the Viteyes Complete product is. I mean, we've tried to
 - the Viteyes Complete product is. I mean, we've tried to identify all the ones that had the amounts of the ingredients --
- 8 MAGISTRATE JUDGE FELDMAN: Is this being sold on 9 your website? Is this -- what is the composition of the 08:44:07AM10 Viteyes?

11

12

13

14

16

17

18

19

21

22

08:44:19AM15

08:44:37AM20

- MR. TOBIN: It's just a variation of our other formulas. It is available on the company's website, or at least it was. I don't know if it still is being sold, but it certainly was.
- MR. KLINE: Well, I mean, if he can tell me what the amounts of the ingredients are, I mean, if it was probably being sold when this lawsuit began and we were aware of it, I'm assuming it was outside the patent, but --
- magistrate judge feldman: Okay. You take this patent very seriously. I have to believe that if there was something out there that was conceivably within the patent, you would be suing on it.
- You also mention in your memorandum of law that you

 24 were worried about modifications to current products. What's

 08:45:01AM25 the difference between a future product and a modification to

1 | a current product?

08:45:13AM 5

08:45:25AM10

08:45:44AM15

08:46:07AM20

08:46:17AM25

6

7

8

9

11

12

13

14

16

17

18

19

21

22

23

24

MR. TOBIN: I think in some instances they would

fall in the same category. It would -- it could be a future

product if there's a modification made.

For example, if one of the components was changed or the concentration of one of the components was changed.

MAGISTRATE JUDGE FELDMAN: That would be a future product if you changed it? Okay, they're the same thing.

So the point of *Hillman* was that even though the defendant claimed there was a case or controversy over future products, the Court disagreed and said that a case or controversy sufficient to maintain jurisdiction can't be based on a fear of litigation over future products.

If the dismissal here immunizes you from suit for infringement over past or current products that could possibly infringe on the '522 patent, isn't all you're left with then a fear of litigation of a product that has yet to come to market, and under the holding of Hillman, is that not enough for a case or controversy?

MR. TOBIN: Well, I think, number one, it's the products that are -- that could have been covered by the complaint. So there's also the issue with that Viteyes Complete product.

But I would note, Your Honor, I think the proposal by Bausch indicates that they want it not just dismissed with

- 1 period. They want it dismissed with prejudice with several
- 2 qualifiers, one of which being that it is limited in some way
- 3 to Vitamin Health; another way that it's limited to the
- 4 certain products.
- 08:46:36AM 5

 - 6 dismissing the case with prejudice period and dismissing the

And I think that there's a difference between

- 7 case with prejudice with additional caveats.
- 8 MAGISTRATE JUDGE FELDMAN: I understand. Which is
- 9 | why I've been exploring your concern about additional caveats.
- 08:46:52AM10 | There isn't a single product that I know of that you've
 - 11 mentioned to me that you've created a record that you have any
 - 12 reason to be concerned about. You know your products.
 - MR. TOBIN: I think, Your Honor, I mean, this could
- 14 be something to dispute another day and there could be other
- 08:47:07AM15 | issues that come up as a result of this.
 - 16 I think that if they're looking to have this case
 - 17 dismissed with prejudice, and if this case is going to be
 - 18 dismissed with prejudice, especially when we've gone
 - 19 through -- I mean, and we've spent a long time on this, we
 - 08:47:19AM20 don't want to face it again.
 - 21 You know, defendant just asked for a Markman ruling
 - 22 three weeks ago on an issue and thereby rendered the claim
 - 23 invalid.
 - 24 MAGISTRATE JUDGE FELDMAN: I feel for you, okay? I
- 08:47:32AM25 do. But I've got to look at the law on this.

And when you look at prejudice, I think the law is 1 2 if you're put in the same spot you would be put in had you prevailed, okay? You have no legal prejudice. Those are the 3 cases that I've read. In other words, it's like you'd gone to trial and 08:47:56AM 5 prevailed on this. You get the same benefits you would have 6 gotten if the jury verdict came in your favor on the '522 7 8 patent. MR. TOBIN: Your Honor, I think what you're saying 9 is definitely -- I understand where you're coming from. 08:48:07AM10 11 I'll say this: If the case is dismissed with prejudice 12 period, in some ways that would be similar to a jury rendering 13 a verdict. If the claim is dismissed with prejudice with 14 08:48:24AM15 qualifiers of any sort, that is not consistent with how the 16 jury would be ruling. 17 MAGISTRATE JUDGE FELDMAN: I don't know of any 18 qualifiers on a dismissal with prejudice. 19 Now, whatever preclusive effect you would have gained by going to trial and winning, you get the same 08:48:39AM20 21 preclusive effect. MR. TOBIN: Understood, Your Honor. Are you asking 2.2 23 that if there's an issue, if it's just dismissed with

MAGISTRATE JUDGE FELDMAN: Correct. I already said

prejudice period?

24

08:48:50AM25

- I'm not going to dismiss it without prejudice. 1 2 MR. TOBIN: But if it's dismissed with prejudice, there wouldn't be other qualifiers that went along with it? 3 MAGISTRATE JUDGE FELDMAN: No. It would be a 4 dismissal with prejudice. 08:49:01AM 5 MR. TOBIN: Okay. Your Honor, the only thing that I 6 would say that comes out of that is the additional 7 considerations that could effect Vitamin Health would be, for 8 example, as relates to these same products which are at issue 08:49:13AM10 in this litigation and covered by the complaint in this case, 11 there could be the possibility of, for example, Vitamin 12 Health's manufacturer being sued. 13 As this Court is well aware, that's a sensitive issue in this case. 14 08:49:25AM15 MAGISTRATE JUDGE FELDMAN: It is. But even the case 16 you cited to me, the Dow Jones case, you know, there was a 17 issue there about their successors or their customers, and it 18 said it didn't prevent the lack of subject matter 19 jurisdiction. I understand you're trying to protect them, but I 08:49:42AM20 21 don't think they would be protected if you won.
- MR. TOBIN: Well, I think, Your Honor, the Court
 pointed us to the Hillman case, and the Hillman case -- I
 mean, those additional protections were provided, at least in
 part, through that covenant not to sue. And that was part of

1 | the resolution of the case and controversy.

08:50:09AM 5

08:50:19AM10

08:50:28AM15

08:50:41AM20

08:50:51AM25

6

7

8

9

11

12

13

14

16

17

18

19

21

2.2

23

2.4

2 MAGISTRATE JUDGE FELDMAN: I understand that. But I
3 don't have those customers in front of me. They're not part
4 of this lawsuit.

I don't think there's anything I can do or anything you would have been able to do in this lawsuit to bring them in.

MR. TOBIN: I don't know that in the Hillman matter, though, Your Honor, that the customers were part of that lawsuit either.

MAGISTRATE JUDGE FELDMAN: I understand, I
understand.

MR. DOMBROWSKI: Your Honor, can I make one point just to address his point about the qualifiers? I think we could make more clear in our motion, but the dismissal with prejudice has the effect of what we're saying it would have an effect of -- be limited to Vitamin Health and to the specific accused products in this case.

So we weren't asking for additional limitations to be imposed on it. That is the effect of the dismissal with prejudice on our --

MAGISTRATE JUDGE FELDMAN: Exactly. I'm not putting any qualifiers on a dismissal with prejudice. Because if I do, then it's not really truly a dismissal with prejudice and the analysis is far different.

I think if it was a dismissal without prejudice, 1 2 given the status of this case and the posture in which you're making the motion, it would be a lot tougher. In fact, I 3 think I would rule in Vitamin Health's favor. Okay, anything else on this issue? 08:51:05AM 5 MR. TOBIN: The only other issue we would note, Your 6 Honor, I don't know if it's an issue for now or for down the 7 road, but to the extent that this matter was dismissed as it 8 relates to the motion to dismiss, we would want the fees that we've incurred as it relates to --08:51:20AM10 11 MAGISTRATE JUDGE FELDMAN: Okay, I'll get to that in 12 a minute. 13 MR. TOBIN: Sure. 14 MAGISTRATE JUDGE FELDMAN: All right. I'm ready to 08:51:26AM15 rule on this and I'm going to read my decision into the 16 record. 17 A jury trial in this matter is scheduled to 18 commence on Monday, August 1st, 2016. 19 On Wednesday, July 26th Bausch & Lomb filed an 08:51:38AM20 unanticipated motion for dismissal of Counts 2 and 3 of the 21 second amended complaint. 2.2 Their motion requested in the first instance 23 dismissal without prejudice; or in the alternative, dismissal 24 with prejudice.

08:51:53AM25

I ordered expedited briefing, which was completed

- 1 yesterday. Yesterday I also notified counsel that I was not 2 inclined to dismiss these claims without prejudice.
- This morning we completed a hearing on this motion.

 4 Based on the law and the arguments of counsel, I am granting

 08:52:11AM 5 Bausch & Lomb's motion to dismiss Counts 2 and 3 with

 6 prejudice.

7

8

11

12

13

14

16

17

18

19

21

22

23

24

08:52:25AM10

08:52:45AM15

08:53:08AM20

- Ordinarily I would issue a written decision, but because this is Friday and jury selection starts Monday morning, I am compelled to write -- or excuse me, I am compelled to issue an oral decision which I will now read into the record.
- A voluntary dismissal with prejudice is generally considered to be an adjudication on the merits with full preclusive effect. I'm citing Bioxy, Inc. vs. Birko, Corporation, 935 F.Supp. 737, at page 741, which is an Eastern District of North Carolina case from 1996.
- Indeed, "it is generally considered an abuse of discretion for a court to deny a plaintiff's request for voluntary dismissal with prejudice."
- I'm citing Degussa Admixtures, Inc. vs. Burnett, 471 F.Supp.2d 848, at page 852, a Western District of Michigan case decided in 2007, which relied on a case called Smoot vs. Fox, 340 F.2d 301, at page 303, a Sixth Circuit case decided in 1964.
- 08:53:41AM25 Where a plaintiff's Rule 41(a)(2) motion

"specifically requests dismissal with prejudice, it has been
held that the District Court must grant that request, relying
on Professors Wright and Miller's treatise Federal Practice

and Procedure, Section 2367, third edition published in 2008.

That quote was used in *United States*, ex rel McLain vs. Fluor Enterprises, Inc., which was an Eastern District of Louisiana case decided March 15th, 2016, and is found at 2016 WL 1031324.

The granting of plaintiff's voluntary motion to dismiss with prejudice essentially puts the defendant in the same position as if they had gone to trial and prevailed on the counts subject to dismissal.

The rights and remedies garnered by the defendant as a result of the dismissal with prejudice are equal to those obtained had there been a finding in their favor, which is why there is no legal prejudice from this type of dismissal.

"No matter when a dismissal with prejudice is granted, it does not harm the defendant. The defendant receives all that he would have received had the case been completed." That quote is from Schwarz vs. Folloder, 767 F.2d 125, at page 129, a Fifth Circuit case decided in 1985.

Vitamin Health opposed dismissal of the two counts even with prejudice. They have not cited to the Court any cases where a court has refused to grant a dismissal with prejudice, but argue that a dismissal is unfair and improper

08:54:07AM 5

4

6

7

8

9

08:54:35AM10

12

14

11

13

08:54:52AM15

16

17

18 19

08:55:11am20

21

22

23

24

08:55:40AM25

- without an open-ended and unrestricted promise from
- 2 Bausch & Lomb that Bausch & Lomb will not sue Vitamin Health
- 3 for not only past and current products, but also future
- 4 products.

08:55:55AM 5

- Again, Vitamin Health has not pointed to any case,
- patent or otherwise, in which a patent holder was required to 6
- covenant not to sue for possible infringement on any future 7
- product the competitor might market during the life of the 8
- 9 patent. I could not find any such case either.

08:56:12AM10

11 relevant to this issue was Hillman Group vs. Minute Key, found

Indeed, the only patent case the Court found

- at 2014 WL 4064187, a Southern District of Ohio case decided 12
- 13 August 15th, 2014.

14 Although the facts in Hillman involved a patent

08:56:30AM15 infringement action by a plaintiff in a declaratory judgment

- action as to patent validity by the defendant, the issue of
- 17 case or controversy arose when the plaintiff withdrew its
- 18 infringement action and promised not to sue the defendant for
- 19 current or past products alleged to have been infringing on
- 08:56:47AM20 the patent.

21

16

- The defendant still wanted the Court to maintain
- jurisdiction over the declaratory judgment action, but the 22
- 23 Court found there was no longer a case or controversy.
- 24 The Court explained as follows, and I'm quoting,
- 08:57:01AM25 "as the Supreme Court has noted, plaintiff may not like --

excuse me, plaintiff may not obtain a declaratory judgment 1 2 merely because it would like an advisory opinion on whether it would be liable for patent infringement if it were to initiate some merely contemplated activity. 4

Plaintiff must be engaged in the actual making, selling or using activity subject to an infringement charge or must have made meaningful preparation for such activity. actual controversy cannot be based on a fear of litigation over future products." That's from page 5 of the Hillman decision, and I've omitted internal quotations and citations.

I find the Hillman analysis and logic to be equally applicable here. There is no evidence that there are any current or past Vitamin Health products that would not be subject to the benefits afforded by dismissing the '522 claims with prejudice.

There is no evidence or suggestion that Vitamin Health has made "meaningful preparations" for future products or future activity that could be considered infringing on the '522 patent.

And as I previously explained, an actual case or controversy sufficient to confer federal jurisdiction cannot be based on a fear Vitamin Health may have over future litigation with respect to future products.

The same analysis holds true for Bausch & Lomb's motion to dismiss Count 3 of the complaint with respect to

08:57:18AM 5

6

3

8

11

12

7

08:57:38AM10

13

14 08:57:59AM15

16

18

19

17

08:58:13AM20

22

21

23

24

08:58:30AM25

alleged false advertising as to Vitamin Health's marketing of 2 its 25 milligram zinc products. By dismissing these claims with prejudice, Vitamin Health is put in the same position as 3 it would be had it prevailed at trial. For these reasons Vitamin Health's motion to 08:58:48AM 5 dismiss claims 2 and 3 is granted. 6 Now, how does that simplify your case? 7 MR. DOMBROWSKI: I think for each of our experts, it 8 9 reduces the testimony they're going to be giving. MAGISTRATE JUDGE FELDMAN: We would have the same 08:59:09AM10 11 number of witnesses, but expert testimony would be limited to 12 the --13 MR. DOMBROWSKI: Correct. I don't think our witness 14 list changes as a result. 08:59:19AM15 MR. KLINE: Doesn't remove any witnesses. It may remove some of the deposition designations, but that's --16 17 MAGISTRATE JUDGE FELDMAN: Can you let me know by 18 the end of today? Because I don't want to spend time going over depositions that I don't have to. 19 08:59:31AM20 How about from your point of view? 21 MR. TOBIN: Your Honor, I think it may make some I've got a quick question of clarification on that, 22 changes. 23 though. 24 You mentioned at the end of the decision 25

milligram zinc products. Just to clarify, the Order of

08:59:40AM25

```
Dismissal with prejudice relates to all of Vitamin Health's
       2
          current products as well as the products that are covered by
          the patent, which would include Vitamin Health's 80 milligram
       3
          products -- both 80 milligram zinc, 2 milligrams of copper as
          well as 80 milligrams of zinc, 2.8 milligrams of copper.
09:00:01AM 5
                      MAGISTRATE JUDGE FELDMAN: Any false advertising
       6
       7
          claim made with respect to the '522 patent is dismissed with
          prejudice.
       8
       9
                      MR. TOBIN: On the patent side, it's any of Vitamin
          Health's products?
09:00:15AM10
      11
                      MAGISTRATE JUDGE FELDMAN: Past or current products.
      12
                      MR. TOBIN: Okay, thank you.
      13
                      MAGISTRATE JUDGE FELDMAN: Okay, with respect to --
                      MR. TOBIN: Your Honor, just -- I'm sorry. So the
      14
09:00:35AM15
          '522 patent's claim is dismissed with prejudice as it relates
      16
          to any of Vitamin Health's current or former products.
      17
                      And then the false advertising claim is just
      18
          dismissed with prejudice as relates to everything that was
      19
          described in the complaint, correct?
09:00:52AM20
                      MAGISTRATE JUDGE FELDMAN: Do you agree with that?
      21
                      MR. KLINE: I think so. I think he's referring
          to the false advertising claim that we had in our Count 3,
      22
      23
          yeah.
      24
                      MAGISTRATE JUDGE FELDMAN: Okay. You won the false
```

advertising claim in Count 3. Whatever -- whatever you --

09:01:07AM25

benefit you could have gotten from that you now have. 2 MR. SUSSER: Your Honor, on the question of streamlining -- is it okay if I sit? 3 4 MAGISTRATE JUDGE FELDMAN: Yes. MR. SUSSER: Other than it will take out some of the 09:01:21AM 5 testimony that we would otherwise adduce, it will not change 6 our witnesses, nor materially effect the exhibits we intend to 7 put in. 8 9 MAGISTRATE JUDGE FELDMAN: How about the designations? 09:01:32AM10 11 MR. SUSSER: It may effect -- I don't think it will 12 eliminate any deponents. It will probably, as Mr. Kline said 13 on his side, limit some of the designations. 14 MAGISTRATE JUDGE FELDMAN: If any of the eliminated 09:01:47AM15 designations have objections, will you let me know by the end 16 of today? 17 MR. SUSSER: Yes, Your Honor. 18 MAGISTRATE JUDGE FELDMAN: Okay. 19 Okay, let's move then to the letters regarding these designations or excerpts of Meyering, Balaram and 09:02:00AM20 Ferris. 21 MR. SUSSER: Your Honor, first I want to thank the 2.2 23 Court for scheduling this hearing to discuss this. 24 it's an important issue and one that will serve everyone well if we can decide in advance. 09:02:16AM25

A large portion of this case relates to the 1 2 allegations by Bausch & Lomb that 25 milligrams is equivalent to 60 to 100 milligrams under the Doctrine of Equivalents. 3 4 The Doctrine of Equivalents measures insubstantial differences or the same function-way-result. Basically, it's 09:02:33AM 5 an interchangeability theory, you can interchange 25 for 80 6 7 and 80 for 25. A second issue that's related is whether Vitamin 8 Health willfully infringed the '297 patent under the Doctrine 9 of Equivalents by knowingly -- with an unjustifiably high risk 09:02:54AM10 11 making, using or selling that 25 milligram product. The testimony that we would like to adduce is 12 13 testimony -- and actually goes beyond, somewhat beyond these designations -- there are other witnesses who will testify to 14 it and documents that relate to it -- is Bausch & Lomb or its 09:03:13AM15 16 agents, and one individual -- and at least one individual from 17 the NEI have said no, 25 is not the same or equivalent to 80 18 milligrams, which falls within the 60 to 100 range. MAGISTRATE JUDGE FELDMAN: None of these 19 09:03:33AM20 designations say that. 21 MR. SUSSER: They do say that 25 and 80 are different. 22 They say --23 MAGISTRATE JUDGE FELDMAN: Just going over them, Mr. 24 Meyering, who is Mr. Meyering?

MR. DOMBROWSKI: He's Bausch & Lomb's -- an

09:03:47AM25

executive at Bausch & Lomb. 1 2 MAGISTRATE JUDGE FELDMAN: Okay. MR. DOMBROWSKI: Most of that testimony, the answers 3 were I don't know. MAGISTRATE JUDGE FELDMAN: That's what I'm saying. 09:03:54AM 5 The first one I got -- and I appreciate you blowing this up 6 because usually I have to wear these, but when I got it I 7 didn't have to wear it. 8 9 Do you believe it also covers 25 milligrams of zinc? I'm looking at the excerpt that was given to me. 09:04:05AM10 11 Witness: I don't know. 12 MR. SUSSER: I don't know what you mean by 13 equivalent he writes -- or his answer is. 14 MAGISTRATE JUDGE FELDMAN: I don't have that. 09:04:23AM15 just have one page. 16 MR. SUSSER: Oh, sorry. 17 MAGISTRATE JUDGE FELDMAN: That's what I have. 18 MR. SUSSER: Let me get Meyering. I just -- before 19 we go down this route, and I'm happy to -- these are 09:04:35AM20 representative of the issue. 21 MAGISTRATE JUDGE FELDMAN: Well, if these are your best representations, I think we have a problem. Let me tell 22 23 you where I'm coming from. You know, the cases that I've read 2.4 say this Doctrine of Equivalents is a question -- Doctrine of

Equivalents is a question for experts, or at least a person of

09:04:51AM25

1	ordinary skill in the art.
2	I don't know from these designations that even if
3	this was a person of ordinary skill in the art and you
4	qualified for that position, that there's anything here that
09:05:15AM 5	would be admissible.
6	Meyering is I don't know, at least and all I'm
7	going on is the excerpts you provided.
8	Balaram, who is Balaram?
9	MR. KLINE: She's a former Bausch & Lomb employee
09:05:27Ам10	who was in the Medical Department, I guess, helping with
11	marketing.
12	MR. DOMBROWSKI: Can I add, Your Honor, too, that
13	Meyering is a marketing person, too, to give you his role at
14	Bausch & Lomb.
09:05:37AM15	MAGISTRATE JUDGE FELDMAN: I don't know who these
16	people are. I'm just basing it on what I have.
17	Are those two products equivalent?
18	Answer: I don't know what you mean by equivalent.
19	Question: The same.
09:05:46Ам20	Answer: They're different. Obviously one has more
21	zinc than the other.
22	Okay. Do they have the same effect?
23	I don't know. Effect for what?
24	It goes on, and on the next page at line 14 and 15,
09:06:01AM25	the same purpose as it relates to age-related macular

```
degeneration?
       1
       2
                      Answer: I don't know.
       3
                      The last page: I don't have the expertise to say
       4
          categorically yes.
                      Ouestion: So you don't know?
09:06:12AM 5
                      Answer: Yes, I don't know.
       6
                      Now, I want to leave the Ferris thing alone for a
       7
          second, but with respect to those two, unless there's a better
       8
          foundation made that this is a person of skill in the art
          that's capable of giving an opinion on the Doctrine of
09:06:26AM10
      11
          Equivalents as to whether the differences are insubstantial, I
      12
          wouldn't allow it on the basis of relevance.
      13
                      There's nothing -- there's no opinion here upon
      14
          anything.
                      MR. SUSSER: Your Honor, if I may?
09:06:44AM15
      16
                      MAGISTRATE JUDGE FELDMAN: Yeah.
      17
                      MR. SUSSER: Couple things. I'm happy to -- there
          are more -- there are more references. We're trying, in the
      18
      19
          interest of time --
09:06:54AM20
                      MAGISTRATE JUDGE FELDMAN: I thought you gave me
      21
          your best ones?
      2.2
                      MR. SUSSER: Actually, they're not the best ones,
      23
          okay? So we have -- if you want better ones where they
          actually say they're not the same -- with AREDS 2 was not
      24
09:07:08AM25
          powered to test equivalence.
```

Remember, what they're saying, Your Honor, is 25 is 1 2 obviously different from 80, but AREDS 2 converts 80 into 25. AREDS 2 basically says they're equivalent. 3 And there are witnesses, their witnesses, several, 4 who say the AREDS 2 study is not powered to make -- to test 09:07:24AM 5 equivalence. It's not designed to test equivalence. 6 And Dr. Bressler, their expert, says that. 7 Ferris, Dr. Ferris of the NEI, says that. Emily Chew of the 8 NEI says that. MAGISTRATE JUDGE FELDMAN: Who is going to be 09:07:43AM10 11 testifying on the Doctrine of Equivalents for Bausch & Lomb? MR. DOMBROWSKI: Dr. Johnson. 12 13 MAGISTRATE JUDGE FELDMAN: Dr. Johnson, you can cross-examine her until the cows come home on it. 14 09:07:52AM15 MR. SUSSER: But, Your Honor, what we would want to do -- what I think would be very important for the jury, 16 17 especially since it's the subjective -- we're being attacked 18 for willful infringement, that we knowingly infringed. 19 MAGISTRATE JUDGE FELDMAN: That's your state of Whether they thought it was equivalent or not is mind. 09:08:07AM20 21 irrelevant to your state of mind. MR. SUSSER: Well, I don't think it's irrelevant, 2.2 23 Your Honor, insofar as if the jury hears that Bausch, Bausch 24 representatives, Bausch's expert, the NEI believe (a) 25 is

not equivalent to 80; and (b), that the AREDS 2 study was not

09:08:27AM25

- designed to test that equivalency, the jury will be more
 likely to believe Aaron's view that he did not think that they
 were equivalent.
- MAGISTRATE JUDGE FELDMAN: I haven't seen that

 19:08:40AM 5 testimony, if you have that testimony. It's just not in the

 2 submissions that you made.

7

8

11

12

13

14

16

17

18

19

21

22

09:08:54AM10

09:09:15AM15

09:09:30AM20

- Now, we don't have a lot of time here. I'm basing my ruling on what you've given me. If you have other evidence that's better than this, I'll consider it, but I forget the name of the case, it's the Aqua something case, Federal Circuit, which lays out what you need to do to prove the Doctrine of Equivalents.
- And don't get me wrong here, okay? I don't think their position on the Doctrine of Equivalents is a slam dunk. Far from it, okay? Just because they say it's equivalent doesn't mean it's equivalent.
- And whether the jury would find 25 and 80 equivalent, you know, that's what the jury's for.
- But the proof that's admissible on that has really been defined by the Federal Circuit. And it's got to be from someone, not a lay person, but someone who is qualified as a person of ordinary skill in the art.
- I don't necessarily think it has to be someone who
 is qualified as an expert, but I do think it has to be someone
 who
 who is qualified as a person of skill in the art, to offer

their opinion on either the three factor test or on whether
the differences are insubstantial; whether the competitor's
changes are so insubstantial that it's unfair to the patent

4 holder.

And, you know, what I would prefer, if you make a further motion on this, is to give me some cases where this type of testimony you're offering would be admissible.

I'm hesitating on the third witness, which is the inventor. Is this witness testifying live, or no?

MR. DOMBROWSKI: No.

MAGISTRATE JUDGE FELDMAN: Okay. You know, the excerpts that you gave me, I think they would be a person qualified in the skill of the art -- or excuse me, a person of ordinary skill in the art, regardless of whether they're proffered as an expert or not.

But the testimony you're giving me doesn't support what you want to use it for. You know, I don't know what you mean by equivalent. They're different. Okay. Do they have the same effect? I don't know. Excuse me, I'm looking at the wrong one.

He goes I don't understand the question, but I'll answer it to the best of my ability. I'm looking at the last page of the submission you gave me, and the answer is the same as I just gave you before, we talked to Bausch & Lomb, asked them to create a formulation that would have, in this case, 80

09:10:15AM 5

7

9

12

09:10:39AM10

13 14 09:10:55AM15

16

17

18

21

22

23

24

19

09:11:14AM20

09:11:27AM25

milligrams of zinc on the formulation, and whatever they did, 2 that's what they did. I don't -- I wouldn't second-guess 3 them. 4 I really don't understand that answer because there's no context to it, but that one, if there was context 09:11:39AM 5 to it, he is the inventor, I assume it's a he --6 MR. DOMBROWSKI: Yes. 7 MAGISTRATE JUDGE FELDMAN: -- I think I'd allow it 8 9 if there was some context to it. MR. DOMBROWSKI: Your Honor, part of it is not just 09:11:53AM10 11 asking who they were asking of the other witnesses, but all of 12 these questions they're just asking about equivalent and 13 sameness, just using those words. 14 They're not laying out the test. So even if this 09:12:04AM15 was a proper person, they're not setting up this question to 16 get the right answer. 17 MAGISTRATE JUDGE FELDMAN: So that's why -- I've got 18 redacted deposition testimony. I really need more than I have 19 here. But of the three of them, I think this is a person 09:12:13AM20 21 that would be of ordinary skill in the art. And if they actually had testimony that would be relevant to the Doctrine 2.2 23 of Equivalents, I think I'd allow it.

MR. SUSSER: Your Honor, may I respond?

MAGISTRATE JUDGE FELDMAN: Yes.

MR. SUSSER: I'll confess, this is a very important 1 2 issue for Vitamin Health so I do want to fight -- give it my best fight. 3 4 I did not put forward the best excerpts. I will do that, and we will submit to the Court by Monday morning 09:12:39AM 5 excerpts that are representative of those two points. One, 6 that the AREDS 2 study was not powered to test equivalency; 7 and number two, that people on their side, people of ordinary 8 9 skill in the art believe them not to be equivalent. I would say this, however, if I could just finish? 09:13:00AM10 11 MAGISTRATE JUDGE FELDMAN: Mm-hmm. MR. SUSSER: Dr. Johnson defines a person of 12 13 ordinary skill in the art, what she believes. First she says it's someone with a medical type degree in eye health, and 14 09:13:14AM15 some experience with visual loss. Then she says "alternatively, a POSA, person of 16 17 ordinary skill in the art, at the time could have been a person with a bachelor's degree with a greater number of years 18 19 of experience. 09:13:31AM20 Now, all the people that we are proposing meet 21 Dr. Johnson's own definition of person of ordinary skill in the art. That's the first point. 22 23 The second point is --24 MAGISTRATE JUDGE FELDMAN: Let me say this:

a bachelor's degree and I wouldn't be an ordinary -- a person

09:13:44AM25

of ordinary skill in the art. I think it's got to be 1 2 something more than having a bachelor's degree. It's got to be a bachelor's degree in some specific area of --3 4 MR. SUSSER: She says with a greater number of years 09:13:57AM 5 of -- I'm quoting exactly. MAGISTRATE JUDGE FELDMAN: Greater number of what 6 7 years? MR. SUSSER: Years of experience in -- in the 8 9 nutritional supplement area, including --09:14:07AM10 MAGISTRATE JUDGE FELDMAN: Okay. 11 MR. SUSSER: -- so all of these people have many 12 years of experience in the nutritional supplement area and a 13 bachelor's degree at the minimum. 14 Now, Dr. Balaram was the medical head of this 09:14:18AM15 particular product. 16 Robert Meyering has worked in this field for 30, 40 17 years first at stores, then at Bausch. He knows this stuff, 18 he markets it, he sells it, he talks about it all the time. 19 These are people who actually know. They are people who are ordinary skill in the art. 09:14:32AM20 Then I would cite the Court to the Hilton Davis 21 Chem Co. vs. Warner Jenkinson where the Federal Circuit 2.2 23 en banc said we're going to restate our position on Doctrine 24 of Equivalents. And one of the things they say, and I have this decision here --09:14:47AM25

```
MAGISTRATE JUDGE FELDMAN: I'm familiar with the
       1
       2
          decision.
                      MR. SUSSER: They focus on is it interchangeable to
       3
          a person of ordinary skill in the art. All of the quotes
       4
          that -- I will give the quote Monday morning on this subject,
09:14:55AM 5
          on the subject of this, are we don't think it's
       6
          interchangeable. They are people of ordinary skill in the art
       7
          who say this is not interchangeable.
       8
       9
                      That's critical for us to get in front of the jury
          not only to defend against infringement on 25, but on
09:15:10AM10
      11
          willfulness as well.
                      And so when the jury hears, we believe, that
      12
      13
          Dr. Ferris of the NEI, Dr. Chew of the NEI, Susan Bressler,
          Dr. Bressler their expert witness, Robert Meyering, John
      14
          Ferris, Mimi Balaram the medical director, they're all saying
09:15:31AM15
      16
          AREDS 2 is not powered for equivalence, number one.
      17
                      And number two --
      18
                      MAGISTRATE JUDGE FELDMAN: What's that mean, AREDS 2
      19
          is not powered for equivalence?
09:15:44AM20
                      MR. SUSSER: It means the study was not designed to
      21
          test whether they were equivalent. You can't say that.
      2.2
                      Dr. Bressler said, look, you can't say they're
          equivalent with the testing that was done on AREDS 2.
      23
      24
          inadequate.
```

09:15:54AM25

It was a limited test for limited purposes and it

wasn't designed -- the study itself doesn't purport to be an
equivalency study.

So when they hear that, Your Honor, that is going to help our defense enormously, we believe, which is why it's so important.

These are all people of ordinary skill in the art, they're experts in this field, in the nutritional field, and they've all said it's not interchangeable.

Under the Hilton Davis case --

MAGISTRATE JUDGE FELDMAN: Okay, let me cut this short a little bit. There's two issues here. One I've said, I think it's the Aqua Tek case, it may be T-E-K, that deals with, you know, what type of testimony is relevant to the Doctrine of Equivalents, but it's got to be somebody -- a person of ordinary skill in the art.

But, second of all, even if you had that person, you have to show that the testimony you're offering says what you say it says, and right now it doesn't, at least with these experts.

MR. SUSSER: That's fair. And that's because I mischose my excerpts. Please allow me, Your Honor, by Monday to give you some better experts.

MAGISTRATE JUDGE FELDMAN: I will. And if you have a memorandum of law attached which sets forth, particularly on this issue of willfulness, how testimony on the Doctrine of

09:16:08AM 5

3

4

6

7

8

9

11

12

16

17

21

22

24

09:16:20am10

13 14

09:16:39Ам15

18 19

09:16:53AM20

23

09:17:06AM25

- 1 Equivalents can be transferred to the issue of willfulness, I would be interested in that too.
- MR. SUSSER: In the meantime, Your Honor, could I

 4 hand to the Court -- and of course opposing counsel -- a short

 6 case?

7 | MAGISTRATE JUDGE FELDMAN: Okay.

8

9

11

12

13

14

16

17

18

09:17:29AM10

09:17:42AM15

- MR. DOMBROWSKI: Can I make one point, Your Honor?

 Of the witnesses he listed, at least a couple of them are not persons of ordinary skill in the art. Mr. Meyering is a marketing guy, like I said earlier. So he's conflating a lot of witnesses here of what we're talking about.
- MAGISTRATE JUDGE FELDMAN: Right. If there's a dispute of that, then I would have questions asked outside the presence of the jury and I would have to make a determination whether the person is --
- MR. DOMBROWSKI: Sure, I just wanted to clarify that, you know.
- MAGISTRATE JUDGE FELDMAN: Okay. This is not something that's going to come up Monday or Tuesday in the trial?
 - 22 MR. SUSSER: I would like to raise it in my 23 opening.
- MAGISTRATE JUDGE FELDMAN: Okay. Well, as of now op:17:57am25 you can't, but I'll take a look at what you give me on Monday.

1 MR. SUSSER: Thank you, Your Honor.

MAGISTRATE JUDGE FELDMAN: Okay. Okay, to be decided is Bausch & Lomb's motion for summary judgment on validity. We plan on issuing that today.

Also, Vitamin Health's lone remaining summary judgment motion or partial summary judgment motion, the lone remaining issue is the prosecution estoppel argument. We hope to issue a written decision on that today.

With respect to the submissions I asked for on what questions would be given to the jury and what questions would be given or made -- determinations would be made by the Court, on July 26th I issued a decision and I set forth for the parties what issues would be resolved by the Court and what issues would be determined by the jury.

With respect to enablement I said, based on the law, that this was a question for the Court to resolve, but if there were factual disputes over an event, I would allow the jury to resolve that dispute through a specific interrogatory question.

I tried to make clear in my Decision and Order that I issued on the 26th that what I was looking for was a genuine factual dispute over an event as opposed to simply competing expert opinions about the legal significance of an undisputed fact or event.

I've reviewed the questions on enablement that I

09:18:24AM 5

6 7

2

3

4

8

9

_

09:18:45AM10

11

12 13

14

09:19:20AM15

16

17

18 19

09:19:43AM20

0).1).15AM

21

22

23

24

09:20:04AM25

have received from Vitamin Health. Based on my review, I 2 don't belive these questions are regarding a factual dispute as to enablement, but really the questions that go to the 3 ultimate determination that I need to make in whether a person of ordinary skill in the art -- excuse me, whether the 09:20:26AM 5 specification describes the invention in such a way to enable 6 a person of ordinary skill in the art to make and use the 7 8 invention. 9 So that the questions that are posed by Vitamin Health, to the extent they need to be answered, will be 09:20:48AM10 11 answered by the Court based upon evidence at trial ,and I will 12 not be submitting those particular questions to the jury 13 because I think they are the ultimate issue that needs to be decided and not really a factual -- genuine factual dispute. 14 With respect to the schedule --09:21:06AM15 16 MR. DOMBROWSKI: Your Honor, can I ask about that 17 last issue? A few of the equitable defenses have not clearly 18

MR. DOMBROWSKI: Your Honor, can I ask about that last issue? A few of the equitable defenses have not clearly been laid out as going to the Court, but I think you mentioned in the first pretrial conference, which we don't have a transcript of, that they will be going to you, which are laches, acquiescence, waiver and equitable estoppel.

MAGISTRATE JUDGE FELDMAN: I don't think there were any dispute as to those. That's why I didn't.

MR. DOMBROWSKI: Just clarifying. Thank you.

MAGISTRATE JUDGE FELDMAN: So I want to talk about

24 09:21:30AM25

09:21:22AM20

19

21

2.2

23

- the schedule. I'm thinking that the dropping of those two
 counts and the summary judgment motion may have shortened the
 trial. Am I correct on that?
- MR. KLINE: Your Honor, that's correct. And just so

 99:21:51AM 5 you know, we have spoken to the other side about streamlining

 6 the number of products, and we've grouped them -- I think

 7 we're in agreement -- we have six groups of the 16 products.

8

9

11

12

13

14

16

17

18

19

21

22

23

24

09:22:10AM10

09:22:20AM15

09:22:39AM20

09:22:58AM25

- We're down to one representative product from each of those groups. Now, three of those groups were the subject of the summary judgment, so we're not going to have to walk through all those.
- So we're really down to, at least for infringement, just three groups with one representative product for each one.

And we're only asserting claims 1, 19 and 31, which are the same ones that were part of the summary judgment motion. So I think that does streamline it quite a bit.

The other thing, we're working with them is how to handle -- obviously, because of the ruling on summary judgment on some of the part, you know, some of it has applicability to these other products because they kept all the ingredients the same except changed one, and we're trying to work with them on, hopefully, a stipulation where we can come to something like based on the Court's claim construction, the parties agree it literally meets claims, you know, element A, B and C.

The only issue to be presented is 2.8. And that will 2 streamline it too. MAGISTRATE JUDGE FELDMAN: Are you confident you'll 3 4 reach agreement on that? MR. KLINE: Unfortunately, I've been speaking with 09:23:12AM 5 Mr. Carlson, and he's not here. But it's my understanding 6 they're agreeable to that. 7 And if -- I guess Mr. Tobin or Mr. Susser can tell 8 9 me differently. MR. TOBIN: I think we've generally narrowed and 09:23:26AM10 11 we're in agreement. I think there may be one or two minor 12 issues left as it relates to one of the groupings, but 13 generally I think we're in agreement. 14 MAGISTRATE JUDGE FELDMAN: Okay. And you'll have 09:23:37AM15 the physical products that you're going to use in court? 16 MR. KLINE: Correct, to the extent -- yeah, right. 17 MR. DOMBROWSKI: I think we do have physical 18 exhibits, yes. 19 MAGISTRATE JUDGE FELDMAN: How much shorter do you think that makes your presentation? 09:23:55AM20 21 MR. KLINE: We haven't added it up. Certainly it cuts out a lot because of the inducement and the false 22 23 advertising issues. I would say -- I would say it probably 2.4 reduced it 25% at least.

MAGISTRATE JUDGE FELDMAN: Okay. With respect to

09:24:17AM25

damages, how are you handling the damage testimony for the 1 2 products that summary judgment's granted on? MR. KLINE: We have updated the damage reports based 3 on the updated sales numbers. We have broken it out by these 4 groupings -- the 80 2.0, the 80 2.8 milligram of copper and 09:24:36AM 5 the 25 milligram. 6 MAGISTRATE JUDGE FELDMAN: How do you propose 7 to explain to the jury that they're going to be considering 8 damages on products that they're not hearing about? MR. KLINE: Well, I'm assuming there would be some 09:24:52AM10 11 sort of stipulation because -- saying that these products have 12 already been found to infringe, but they still have their 13 validity argument on. 14 MAGISTRATE JUDGE FELDMAN: I'm not sure I'm going to 09:25:04AM15 tell the jury these products have been found to infringe. I 16 think we've got to work out a sanitized stipulation that 17 you're being asked to determine on these, you're not to 18 consider whether they infringe or not. I think that's --19 MR. SUSSER: I'm worried that if the jury hears that 09:25:18AM20 you've made a decision, they will be against us. 21 MAGISTRATE JUDGE FELDMAN: So I'd like you to work out a different stipulation on that. 22 23 MR. SUSSER: Yes, we will, Your Honor, we'll propose 2.4 something.

MAGISTRATE JUDGE FELDMAN: Okay. So I'm interested

09:25:31AM25

```
to know your thoughts on a schedule. My current thinking now
       2
          is to start at 8:30 and go to 1:30, take two breaks -- this is
          with the jury; and then use the afternoon, maybe come back at
          2:30 or so for testimony on issues that will solely be before
09:25:58AM 5
          me.
                      MR. SUSSER: I think that could work, Your Honor.
       6
                      MAGISTRATE JUDGE FELDMAN: Who are the witnesses
       7
          that are going to testify on the equitable or the legal
       8
          issues?
                      MR. KLINE: They're their issues, so I'm not
09:26:12AM10
      11
          certain.
                      MR. SUSSER: On the equitable issues, Your Honor,
      12
      13
          estoppel and laches, that would be Mr. Shepherd, Aaron
      14
          Shepherd.
09:26:28AM15
                      MAGISTRATE JUDGE FELDMAN: So he's going to be here
          for the whole trial anyway, right?
      16
      17
                      MR. SUSSER: He will be.
      18
                      MAGISTRATE JUDGE FELDMAN: All right. So we'll be
      19
          able to fit him in, okay.
09:26:39AM20
                      MR. SUSSER: Your Honor, if I could just come back
      21
          to one point? We can get the Court those excerpts by
          1 o'clock today. Would it be, just to avoid Tuesday -- Monday
      22
      23
          morning, would it be possible to come back this afternoon and
      24
          just --
```

09:26:53AM25

MAGISTRATE JUDGE FELDMAN: I'm out this afternoon,

which is why I want to do it this morning. 2 MR. SUSSER: Yes. MAGISTRATE JUDGE FELDMAN: I'm going to be working 3 on this all weekend, so if you get it to me --4 MR. SUSSER: We'll get it to you this afternoon for 09:27:01AM 5 sure, Your Honor. I do appreciate that. 6 There was one issue in the letter we didn't address 7 8 and that was the cross-examination issue. 9 MAGISTRATE JUDGE FELDMAN: Explain that to me. MR. SUSSER: Sure. Basically what I'm proposing is 09:27:10AM10 11 the same arrangement that we have for Aaron Shepherd, which is 12 we will call Mr. Shepherd in our case-in-chief, but they will 13 be able to cross-examine him not only on what we ask him about, but anything -- any topic that they've designated from 14 09:27:29AM15 his deposition. So they automatically get a wider swath of 16 territory for cross-examination. 17 We want to do the same thing for Mr. Meyering and 18 Mr. John Ferris, their two fact witnesses. To the extent 19 those individuals don't talk about something being equivalent, 09:27:49AM20 for example, we want to be -- assuming the Court allows it in 21 eventually, we would want to be able to ask them that, about that. And we've designated testimony that would be the topics 2.2 23 we want to ask them about.

They've said -- of course they agreed to Mr.

Shepherd, but they said no as to Meyering and Ferris.

24

09:28:04AM25

```
said maybe you can read them to the jury with our counter
       2
          designations and objections and we don't want to do that.
                                                                       We
          already have too much to read to the jury, the jury's going to
       3
          be bored.
09:28:15AM 5
                      We want -- the witnesses are up there, we're
          telling them the topics. It's just their deposition
       6
       7
          testimony.
                      MAGISTRATE JUDGE FELDMAN: What are the topics
       8
       9
          beyond equivalence?
09:28:26AM10
                      MR. SUSSER: I can't think of any, Your Honor.
      11
                      MAGISTRATE JUDGE FELDMAN: So it really depends on
      12
          my ruling?
      13
                      MR. SUSSER: I'd have to go back and double check
          Meyering and Ferris, but I'm pretty sure most of them would
      14
          be on the Doctrine of Equivalents and whether something is
09:28:40AM15
      16
          interchangeable. And so I think the answer is a qualified
      17
          yes.
      18
                      MAGISTRATE JUDGE FELDMAN: Have you designated all
      19
          those sections that you want to ask them about?
09:28:53AM20
                      MR. SUSSER: Yes, Your Honor.
      21
                      MAGISTRATE JUDGE FELDMAN: Are those designations
          that I have already?
      22
      23
                      MR. SUSSER: Yes, Your Honor.
      24
                      MAGISTRATE JUDGE FELDMAN: Okay. So you want to be
09:28:59AM25
         able to question them live on that?
```

MR. SUSSER: Cross-examine them after they finish 1 their direct, even if it's not raised on direct. 2 3 MAGISTRATE JUDGE FELDMAN: Okay. MR. DOMBROWSKI: Your Honor, a few points on that. 4 One, back to my earlier point, Meyering and John Ferris are 09:29:09AM 5 not experts, they're POSA's. 6 So the Doctrine of Equivalents and the scope of the 7 patent claim questions we think is inappropriate for them as 8 an initial matter. Second of all, Mr. Susser makes it seem like we 09:29:20AM10 11 wanted this Aaron Shepherd deal. This is something they approached us about to have this accomodation so that we 12 13 didn't preempt his live testimony by playing his video or reading his transcript. So it's not like we're seeking this 14 09:29:32AM15 arrangement. 16 And for our witnesses we don't want that 17 arrangement. We don't want the cross blown wide up. We would rather have them play the properly 30(b)(6) designated 18 19 testimony in their case-in-chief. 09:29:43AM20 MAGISTRATE JUDGE FELDMAN: Or they could call them in their case? 21 MR. DOMBROWSKI: They could, although I'll note they 2.2 did not list them on their list of witnesses. 23 MR. SUSSER: Actually, we did, Your Honor. We 24

referenced their witness list, we listed them and their

09:29:51am25

- 1 Rule 30(b)(6) deponents, both of them.
- 2 And the testimony we're asking them about is
- 3 largely, not exclusively, is Rule 30(b)(6) testimony which can
- 4 be used for any purpose at trial.
- 09:30:04AM 5
 - 6 there's something on the Doctrine of Equivalents that they can

MAGISTRATE JUDGE FELDMAN: Assuming I rule that

- 7 ask him about, which right now I haven't seen anything, but
- 8 assuming I see something, do you want to bring them back or do
- 9 you want to allow him to be asked?
- 09:30:21AM10
- MR. DOMBROWSKI: Just allow him to be asked on cross
 - 11 | I suppose.

cases.

- 12 MAGISTRATE JUDGE FELDMAN: That's up to you. I'm
- 13 | not going to force you to do anything. There's a lot of
- 14 strategy that goes into these cases, I know that, I've tried
- 09:30:35AM15
 - So I'm going to let you try your own case, but it's
 - 17 | really an inconvenience to your witness, I guess, that you
 - 18 have to weigh.
 - 19 MR. DOMBROWSKI: Sure, and he's from Florida.
- 09:30:42AM20 mean, we can work it out. I just don't know on the spot.
 - 21 MAGISTRATE JUDGE FELDMAN: Okay. I'm not forcing
 - 22 them to do that. I'm going to first find out if there's
 - 23 anything -- because right now there isn't anything, but you're
 - 24 going to get me something by 1 o'clock today, I want to give
- 09:30:53AM25 you a chance to respond to it. Maybe by the close of business

- 1 | if you get it by 1?
- 2 MR. DOMBROWSKI: Can I make one other point? We
- 3 have served them our objections and counter designations to
- 4 their designations for Mr. Meyering and Mr. Ferris.
- 09:31:05AM 5 But we have not had the whole procedure back and
 - 6 forth. We've not seen their objections to our counter
 - 7 designations because they were given to us, you know, that
 - 8 process has not played out yet.
 - 9 So I'm not sure it's possible to do that by this
 - 09:31:17AM10 afternoon, b ut we can try, but just we have not had the back
 - 11 and forth yet on that.
 - 12 MR. SUSSER: Our --
 - 13 MAGISTRATE JUDGE FELDMAN: I thought you said you
 - 14 designated the Doctrine of Equivalent testimony you want for
 - 09:31:25AM15 | these witnesses?
 - MR. SUSSER: We did. We gave it to them and they
 - 17 objected and counter designated.
 - 18 Our position is we don't want -- we don't need to
 - 19 go through that. You can question him on anything you want on
 - 09:31:36AM20 direct, you can redirect him on that, you can object to our
 - 21 questions at trial if you want.
 - We're asking that it not be done through a
 - 23 deposition designation process.
 - MR. DOMBROWSKI: I guess the reason why I bring that
 - 09:31:49AM25 up is, for instance, the quote from Mr. Meyering that they

```
gave you in the letter is not properly within the 30(b)(6) scope.
```

3

4

6

9

11

12

13

14

16

17

18

19

21

22

23

09:32:01AM 5

09:32:13AM10

09:32:25AM15

09:32:39AM20

So, I mean, that's not even -- there is no 30(b)(6) topic for Mr. Meyering on the scope of the patent claims, for instance, and that's what -- the question was asked to him on that particular portion they gave you.

So that's noted in our objections that we provided them.

MR. SUSSER: They can object -- if they want, they can object at trial if I ask a cross question. I don't believe that I will.

I believe what I'll ask is -- it doesn't need -- he's a fact witness and he's a 30(b)(6) witness, he's testifying as both. He has personal knowledge because he lived through all this; he was the NEI's -- chief communicator with the NEI, et cetera. So he's a personal witness, he's a Rule 30(b)(6).

Most of the topics, if not all, are -- that I will want to ask him about on cross are Rule 30(b)(6) topics. That was key. He testified on a lot of those issues.

MR. DOMBROWSKI: My response is just that particular portion at least they gave you in the letter is not properly 30(b)(6).

MAGISTRATE JUDGE FELDMAN: Okay, let's look at that
09:32:50am25 for a second. If, for example, he convinces me that this is a

```
person of skill in the art, and that there's something that
       2
          he's testified about that goes to a relevant issue on the
          Doctrine of Equivalents --
       3
       4
                      MR. DOMBROWSKI: And is properly 30(b)(6) within
          the scope of their topics.
09:33:04AM 5
                      MAGISTRATE JUDGE FELDMAN: Let's say it's not within
       6
       7
          the scope of their topics.
                      MR. DOMBROWSKI: Then they don't have a right to
       8
       9
          play the deposition in their case-in-chief if he's --
09:33:11AM10
                      MAGISTRATE JUDGE FELDMAN: No, no, he's not playing
      11
          the deposition. He's going to ask him live.
      12
                      MR. DOMBROWSKI: Okay.
      13
                      MAGISTRATE JUDGE FELDMAN: Right?
      14
                      MR. SUSSER: Right. This isn't scripted. This is
09:33:17AM15
          cross-examination.
      16
                      MAGISTRATE JUDGE FELDMAN: Yeah, he's going to ask
      17
          him live.
                      MR. DOMBROWSKI: We're already at the point where
      18
      19
          that's -- okay.
09:33:23AM20
                      MAGISTRATE JUDGE FELDMAN: We're far ahead of where
      21
          we are now. I haven't made a ruling on any of this.
          assuming that he gives me something that says -- from some
      22
      23
          expert that says this person has -- not an expert. From
      2.4
          someone of position of skill in the art, that they have
          something that's relevant to the Doctrine of Equivalents.
09:33:37AM25
```

MR. DOMBROWSKI: My response to that is the deal we made with Aaron Shepherd is that on our cross-examination of him we can go outside the scope of the direct for -- that is within the scope of what we designated properly 30(b)(6) in his transcript.

So to the extent they're going to try to go outside the scope of the direct with Mr. Meyering on testimony that's not properly within the scope of 30(b)(6) designated testimony in his deposition transcripts that's, we believe, improper and should be outside the scope --

MAGISTRATE JUDGE FELDMAN: Maybe I need to take another look at 30(b)(6), but let's say you have somebody who is a 30(b)(6), but also is intricately involved in the facts of the case.

Normally you would be restricted on cross-examination to topics that were testified to on direct examination, but I've had a lot of cases where -- because for convenience of the witnesses they don't want to bring them back and put them on as an adverse witness on their case, they would rather just cross-examine them on the other side.

I don't care what you do, but I don't think someone can escape being asked questions about something they have personal knowledge about simply because they're also designated as a 30(b)(6).

MR. DOMBROWSKI: Okay.

09:34:04AM10

09:34:17AM15

09:34:34AM20

09:34:46AM25

```
MR. SUSSER: Your Honor, I will just add two things.
       1
       2
          One, as far as Aaron Shepherd, that was not my understanding
                        They can question him on 30(b)(6) topics, but
       3
          of the deal.
          also other topics that they designated. That's no problem.
                      MAGISTRATE JUDGE FELDMAN: What about topics they
09:34:59AM 5
          didn't designate? What if they want to ask him about
       6
          something that they have the right to ask him about it, it's
       7
          relevant, that they could call him as their own adverse
       8
       9
          witness --
                      MR. SUSSER: I mean, if it's relevant, it's fine.
09:35:12AM10
      11
          mean --
      12
                      MAGISTRATE JUDGE FELDMAN: My bad.
      13
                      MR. SUSSER: It's relevant, Your Honor -- look, if
      14
          it's relevant, they can ask Aaron Shepherd about it.
09:35:30AM15
          perfectly appropriate.
      16
                      Mr. Meyering, I said to him would your personal
      17
          testimony be any different than your Rule 30(b)(6)? He said
      18
          no, it's the same.
      19
                      I think we're really trying to micromanage
          something that -- it's an organic process.
09:35:41AM20
                                                       There's
          cross-examination, it will flow where it flows. As long as
      21
          the parties stick to relevant information, the jury can
      22
      23
          ultimately sift it out.
      24
                      MAGISTRATE JUDGE FELDMAN: Right. I know you have
09:35:52AM25
          this very specific agreement that you negotiated.
```

But what I'm saying is from my view, I'll enforce 1 2 whatever agreement you want, but it might be simpler if we say a witness will testify once, if that's what you want? 3 MR. SUSSER: I agree to that. 4 09:36:13AM 5 MAGISTRATE JUDGE FELDMAN: And you can ask him questions as though you call him as an adverse witness on your 6 own; or we have a rule that says no, we're gonna play it just 7 by the Federal Rules of Evidence that cross-examination is 8 9 limited to what was gone over on direct examination, and if you want this witness to present something in your case that 09:36:33AM10 11 he didn't or she didn't testify about on direct examination, 12 you have that right, but you've got to wait until the other 13 side rests. 14 So I'm not saying what you should do, but I think 09:36:47AM15 you should think about it because the system that you have 16 now, which is are we inside a designation, are we outside a 17 designation, that's going to require me to become much more 18 familiar with the designations than I am right now and much more familiar with the details of whatever agreement you 19 worked out, and I'm not privy to that. 09:37:04AM20 21 So I think it's cleaner either if you go all the way one way or all the way the other way. 22 23 MR. DOMBROWSKI: I understand.

as I'm concerned, witness by witness. If there's some

MAGISTRATE JUDGE FELDMAN: And you can do it, as far

24

09:37:14AM25

witnesses you want to do that with, that's fine. If there's 2 some you don't want to do that with, that's fine. MR. DOMBROWSKI: That's where we're at right now. 3 Leading up to this we already had this arrangement about Aaron 4 Shepherd. And now just recently it's being blown up into 09:37:25AM 5 these other witness and the dust hasn't settled on all that 6 7 yet. So I guess where we're at is kind of like what you 8 said, we need to determine which witnesses -- what's going to 9 09:37:37AM10 be done with each witness. 11 MAGISTRATE JUDGE FELDMAN: I think that's true. 12 MR. SUSSER: Okay. 13 MAGISTRATE JUDGE FELDMAN: Unless you have a general 14 agreement. 09:37:41AM15 So unless I hear otherwise, I'm either going to 16 enforce whatever agreement you've agreed on or I'm going to 17 enforce the Federal Rules of Evidence. 18 MR. DOMBROWSKI: I think that's what we prefer. 19 have an agreement for Aaron Shepherd. And we're just asking 09:37:54AM20 to enforce the Federal Rules for our witnesses. MR. KLINE: We'll think about it. 21 MAGISTRATE JUDGE FELDMAN: Okay. All right? 2.2 23 MR. DOMBROWSKI: Couple other points to raise. 24 is the preliminary jury instructions, that you said you would

rule on the disputed portions before trial.

09:38:08AM25

We just need to get the jury binders together --1 2 not to obviously force that on you. MAGISTRATE JUDGE FELDMAN: I had forgotten about 3 In terms of preliminary instructions, I think once we 4 get the jury selected, we're going to show them the video and 09:38:19AM 5 hand out the kind of phoney patent that they follow along with 6 the video. 7 MR. DOMBROWSKI: Okay. 8 MAGISTRATE JUDGE FELDMAN: Okay? And then I've got 9 to take a closer look at your preliminary jury instructions. 09:38:31AM10 11 MR. DOMBROWSKI: The thing I'll add to that is in 12 light of the recent developments this week on many fronts, 13 there are other things besides the disputed portions we may 14 need to tweak to make them correct now. 09:38:44AM15 MAGISTRATE JUDGE FELDMAN: Why don't you, by the close of business today, get me a revised preliminary 16 17 instruction? 18 MR. DOMBROWSKI: Okay, thank you. Another small 19 issue is we still have not received the privileged documents 09:38:56AM20 you ordered them to produce which we would like to start 21 processing for our case. MAGISTRATE JUDGE FELDMAN: Do you have those? 2.2 23 MR. TOBIN: We'll get those to them, Your Honor. 24 MAGISTRATE JUDGE FELDMAN: Get those to them by 1 o'clock this afternoon. 09:39:02AM25

MR. TOBIN: One further issue, Your Honor, if I may? 1 2 When we sent the designations to the Court, the parties exchanged designations and objections and what not, and when 3 we submitted them to the Court in the larger form it appears we inadvertently included -- excluded one of the witnesses, 09:39:19AM 5 Emily Chew's designations. It was inadvertent. 6 We sent them to the other side once we realized, 7 and we have a copy here for the other side if they want and 8 one for the Court. MR. DOMBROWSKI: I don't think we're going to fight 09:39:34AM10 11 on that. We're fine with those coming in as it -- we had 12 dealt with them before -- oh, we're talking about Emily Chew? 13 We did not have any objections to those particular portions. 14 MR. TOBIN: There were no objections. I just wanted 09:39:44AM15 to provide the Court with a copy. 16 MAGISTRATE JUDGE FELDMAN: Get me the transcript. But there's no objections I need to rule on? 17 18 MR. DOMBROWSKI: Correct, Your Honor. 19 MR. TOBIN: Correct, Your Honor. MR. DOMBROWSKI: Your Honor, we're confirming, we 09:39:52AM20 21 can respond to whatever they submit by 1 by 5 o'clock today? MAGISTRATE JUDGE FELDMAN: Yes. 2.2 23 MR. DOMBROWSKI: Okay, thank you. 24 MAGISTRATE JUDGE FELDMAN: Okay? All right, see you on Monday. 09:40:19AM25

1	(WHEREUPON, the proceedings adjourned at 9:40 a.m.)
2	* * *
3	CERTIFICATE OF REPORTER
4	
5	In accordance with 28, U.S.C., 753(b), I certify that
6	these original notes are a true and correct record of
7	proceedings in the United States District Court for the
8	Western District of New York before the Honorable Jonathan W.
9	Feldman on July 29th, 2016.
10	
11	S/ Christi A. Macri
12	Christi A. Macri, FAPR-CRR Official Court Reporter
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	